Gilead's HIV Quad Pill Passes Tolerability Test, But Not With A Straight "A"

By and large, Gilead's latest Phase II results for its fixed-dose, four-drug "Quad" regimen for HIV and stand-alone data on its novel GS-9350 booster satisfied clinicians and analysts when it came to the commercially crucial tolerability test